This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Ottawa directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $100,000
Oral Vancomycin for the Prevention of C. difficile Infection in High-Risk HCT and CAR-T Patients (VAPOR-HCT): A Pilot Randomized Placebo-Controlled Trial
CIHR · 2025 · Principal investigator
Oral Vancomycin for the Prevention of C. difficile Infection in High-Risk HCT and CAR-T Patients (VAPOR-HCT): A Pilot Randomized Placebo-Controlled Trial
Principal investigators: MacFadden, Derek R; Atkins, Harold L; Buchan, Catharine A; Cheng, Matthew P; Climans, Troy; Coburn, Bryan A; Daneman, Nick; Gauthier, Karine; Hay, Annette; Kabbani, Dima; Kekre, Natasha; Kennah, Michael; McIntyre, Lauralyn A; Mertz, Dominik; Monteith, Bethany E; Mortimer, Leanne M; Purssell, Andrew; Taljaard, Monica; Tsang, Corey
Keywords: Antimicrobial Resistance; Biomarker; C.Difficile Infection; Chimeric Antigen Receptor T-Cell Therapy; Feasibility; Hematopoietic Stem Cell Transplantation; Microbiome; Pilot; Prophylaxis; Randomized Trial
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.